Development of biocompatible and VEGF-targeted paclitaxel nanodrugs on albumin and graphene oxide dual-carrier for photothermal-triggered drug delivery in vitro and in vivo

Wentao Deng,1,* Juhui Qiu,1,* Shaoting Wang,1 Zhi Yuan,1 Yuefeng Jia,2 Hailin Tan,2 Jiru Lu,1 Ruqiang Zheng1 1Department of Urinary Surgery, Dongying People’s Hospital, Dongying, 2Department of Urinary Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China *Thes...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Deng W, Qiu J, Wang S, Yuan Z, Jia Y, Tan H, Lu J, Zheng R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Paclitaxel Graphene oxide Human serum albumin Tumor targeting Photothermal-triggered tumor therapy Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/488065c708214d0f9c92c05c52e85ac4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:488065c708214d0f9c92c05c52e85ac4
record_format	dspace
spelling	oai:doaj.org-article:488065c708214d0f9c92c05c52e85ac42021-12-02T02:42:31ZDevelopment of biocompatible and VEGF-targeted paclitaxel nanodrugs on albumin and graphene oxide dual-carrier for photothermal-triggered drug delivery in vitro and in vivo1178-2013https://doaj.org/article/488065c708214d0f9c92c05c52e85ac42018-01-01T00:00:00Zhttps://www.dovepress.com/development-of-biocompatible-and-vegf-targeted-paclitaxel-nanodrugs-on-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Wentao Deng,1,* Juhui Qiu,1,* Shaoting Wang,1 Zhi Yuan,1 Yuefeng Jia,2 Hailin Tan,2 Jiru Lu,1 Ruqiang Zheng1 1Department of Urinary Surgery, Dongying People’s Hospital, Dongying, 2Department of Urinary Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China *These authors contributed equally to this work Abstract: In this study, we performed the characterization and synthesis of biocompatible and targeted albumin and graphene oxide (GO) dual-carrier paclitaxel (PTX) nanoparticles for photothermal-triggered tumor therapy. PTX absorbed on GO nanosheets as cores were coated with human serum albumin (HSA), following surface conjugation with monoclonal antibodies (mAb) against vascular endothelial growth factor (VEGF; denoted as mAbVEGF) via polyethylene glycol linker to form targeted nanoparticles (PTX-GHP-VEGF). The spherical nanoparticles were 191±5 nm in size with good stability and biocompatibility. GO functioned as the first carrier and a near infrared absorber that can generate photothermal effects under 5-minute 808-nm laser irradiation to thermal trigger the release of PTX from the second carrier HSA nanoparticles. The mechanism of thermal-triggered drug release was also investigated preliminarily, in which the heat generated by GO induced swelling of PTX-GHP-VEGF nanoparticles which released the drugs. In vitro studies found that PTX-GHP-VEGF can efficiently target human SW-13 adrenocortical carcinoma cells as evaluated by confocal fluorescence microscopy as well as transmission electron microscopy, and showed an obvious thermal-triggered antitumor effect, mediated by apoptosis. Moreover, PTX-GHP-VEGF combined with near infrared irradiation showed specific tumor suppression effects with high survival rate after 100 days of treatment. PTX-GHP-VEGF also demonstrated high biosafety with no adverse effects on normal tissues and organs. These results highlight the remarkable potential of PTX-GHP-VEGF in photothermal controllable tumor treatment. Keywords: paclitaxel, graphene oxide, human serum albumin, tumor targeting, photothermal-triggered tumor therapyDeng WQiu JWang SYuan ZJia YTan HLu JZheng RDove Medical PressarticlePaclitaxelGraphene oxideHuman serum albuminTumor targetingPhotothermal-triggered tumor therapyMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 13, Pp 439-453 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Paclitaxel Graphene oxide Human serum albumin Tumor targeting Photothermal-triggered tumor therapy Medicine (General) R5-920
spellingShingle	Paclitaxel Graphene oxide Human serum albumin Tumor targeting Photothermal-triggered tumor therapy Medicine (General) R5-920 Deng W Qiu J Wang S Yuan Z Jia Y Tan H Lu J Zheng R Development of biocompatible and VEGF-targeted paclitaxel nanodrugs on albumin and graphene oxide dual-carrier for photothermal-triggered drug delivery in vitro and in vivo
description	Wentao Deng,1,* Juhui Qiu,1,* Shaoting Wang,1 Zhi Yuan,1 Yuefeng Jia,2 Hailin Tan,2 Jiru Lu,1 Ruqiang Zheng1 1Department of Urinary Surgery, Dongying People’s Hospital, Dongying, 2Department of Urinary Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China *These authors contributed equally to this work Abstract: In this study, we performed the characterization and synthesis of biocompatible and targeted albumin and graphene oxide (GO) dual-carrier paclitaxel (PTX) nanoparticles for photothermal-triggered tumor therapy. PTX absorbed on GO nanosheets as cores were coated with human serum albumin (HSA), following surface conjugation with monoclonal antibodies (mAb) against vascular endothelial growth factor (VEGF; denoted as mAbVEGF) via polyethylene glycol linker to form targeted nanoparticles (PTX-GHP-VEGF). The spherical nanoparticles were 191±5 nm in size with good stability and biocompatibility. GO functioned as the first carrier and a near infrared absorber that can generate photothermal effects under 5-minute 808-nm laser irradiation to thermal trigger the release of PTX from the second carrier HSA nanoparticles. The mechanism of thermal-triggered drug release was also investigated preliminarily, in which the heat generated by GO induced swelling of PTX-GHP-VEGF nanoparticles which released the drugs. In vitro studies found that PTX-GHP-VEGF can efficiently target human SW-13 adrenocortical carcinoma cells as evaluated by confocal fluorescence microscopy as well as transmission electron microscopy, and showed an obvious thermal-triggered antitumor effect, mediated by apoptosis. Moreover, PTX-GHP-VEGF combined with near infrared irradiation showed specific tumor suppression effects with high survival rate after 100 days of treatment. PTX-GHP-VEGF also demonstrated high biosafety with no adverse effects on normal tissues and organs. These results highlight the remarkable potential of PTX-GHP-VEGF in photothermal controllable tumor treatment. Keywords: paclitaxel, graphene oxide, human serum albumin, tumor targeting, photothermal-triggered tumor therapy
format	article
author	Deng W Qiu J Wang S Yuan Z Jia Y Tan H Lu J Zheng R
author_facet	Deng W Qiu J Wang S Yuan Z Jia Y Tan H Lu J Zheng R
author_sort	Deng W
title	Development of biocompatible and VEGF-targeted paclitaxel nanodrugs on albumin and graphene oxide dual-carrier for photothermal-triggered drug delivery in vitro and in vivo
title_short	Development of biocompatible and VEGF-targeted paclitaxel nanodrugs on albumin and graphene oxide dual-carrier for photothermal-triggered drug delivery in vitro and in vivo
title_full	Development of biocompatible and VEGF-targeted paclitaxel nanodrugs on albumin and graphene oxide dual-carrier for photothermal-triggered drug delivery in vitro and in vivo
title_fullStr	Development of biocompatible and VEGF-targeted paclitaxel nanodrugs on albumin and graphene oxide dual-carrier for photothermal-triggered drug delivery in vitro and in vivo
title_full_unstemmed	Development of biocompatible and VEGF-targeted paclitaxel nanodrugs on albumin and graphene oxide dual-carrier for photothermal-triggered drug delivery in vitro and in vivo
title_sort	development of biocompatible and vegf-targeted paclitaxel nanodrugs on albumin and graphene oxide dual-carrier for photothermal-triggered drug delivery in vitro and in vivo
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/488065c708214d0f9c92c05c52e85ac4
work_keys_str_mv	AT dengw developmentofbiocompatibleandvegftargetedpaclitaxelnanodrugsonalbuminandgrapheneoxidedualcarrierforphotothermaltriggereddrugdeliveryinvitroandinvivo AT qiuj developmentofbiocompatibleandvegftargetedpaclitaxelnanodrugsonalbuminandgrapheneoxidedualcarrierforphotothermaltriggereddrugdeliveryinvitroandinvivo AT wangs developmentofbiocompatibleandvegftargetedpaclitaxelnanodrugsonalbuminandgrapheneoxidedualcarrierforphotothermaltriggereddrugdeliveryinvitroandinvivo AT yuanz developmentofbiocompatibleandvegftargetedpaclitaxelnanodrugsonalbuminandgrapheneoxidedualcarrierforphotothermaltriggereddrugdeliveryinvitroandinvivo AT jiay developmentofbiocompatibleandvegftargetedpaclitaxelnanodrugsonalbuminandgrapheneoxidedualcarrierforphotothermaltriggereddrugdeliveryinvitroandinvivo AT tanh developmentofbiocompatibleandvegftargetedpaclitaxelnanodrugsonalbuminandgrapheneoxidedualcarrierforphotothermaltriggereddrugdeliveryinvitroandinvivo AT luj developmentofbiocompatibleandvegftargetedpaclitaxelnanodrugsonalbuminandgrapheneoxidedualcarrierforphotothermaltriggereddrugdeliveryinvitroandinvivo AT zhengr developmentofbiocompatibleandvegftargetedpaclitaxelnanodrugsonalbuminandgrapheneoxidedualcarrierforphotothermaltriggereddrugdeliveryinvitroandinvivo
_version_	1718402215232667648

Development of biocompatible and VEGF-targeted paclitaxel nanodrugs on albumin and graphene oxide dual-carrier for photothermal-triggered drug delivery in vitro and in vivo

Ejemplares similares